Fluorine Radioisotopes

• 

  Subject Areas on Research

  • (4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography. 
  • 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model. 
  • 18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery. 
  • 3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. 
  • 5-substituted derivatives of 6-halogeno-3-((2-(S)-azetidinyl)methoxy)pyridine and 6-halogeno-3-((2-(S)-pyrrolidinyl)methoxy)pyridine with low picomolar affinity for alpha4beta2 nicotinic acetylcholine receptor and wide range of lipophilicity: potential probes for imaging with positron emission tomography. 
  • 6-[18F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors. 
  • A p-[18F]fluoroethoxyphenyl bicyclic nucleoside analogue as a potential positron emission tomography imaging agent for varicella-zoster virus thymidine kinase gene expression. 
  • ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer. 
  • Accuracy of surface fit registration for PET and MR brain images using full and incomplete brain surfaces. 
  • Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. 
  • An Efficient Method for Labeling Single Domain Antibody Fragments with 18F Using Tetrazine- Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable Linker. 
  • Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. 
  • Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. 
  • Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models. 
  • Detection and quantitation of 17F formation during the cyclotron production of 13N. 
  • Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). 
  • Development of Novel ¹⁸ F-PET Agents for Tumor Hypoxia Imaging. 
  • Dopamine in amygdala gates limbic processing of aversive stimuli in humans. 
  • Effect of secondhand smoke on occupancy of nicotinic acetylcholine receptors in brain. 
  • Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. 
  • FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. 
  • FDG-PET in the selection of brain lesions for biopsy. 
  • Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. 
  • Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation. 
  • Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation. 
  • Fluorine-18 labeled chemotactic peptides: a potential approach for the PET imaging of bacterial infection. 
  • Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation. 
  • Fluorine-18 labeling of monoclonal antibodies and fragments with preservation of immunoreactivity. 
  • Fluorine-18-antimyosin monoclonal antibody fragments: preliminary investigations in a canine myocardial infarct model. 
  • Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. 
  • Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography. 
  • Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. 
  • Functional expression of sodium-glucose transporters in cancer. 
  • Graphical analysis of 2-[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. 
  • Hospice Admission and Survival After ¹⁸ F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. 
  • I-131, I-123, and F-18 FDG-PET imaging in a patient with diffuse sclerosing variant of papillary thyroid cancer. 
  • Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. 
  • Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. 
  • Imaging of pheochromocytoma in 2 dogs using p-[18F] fluorobenzylguanidine. 
  • Impact of short access nicotine self-administration on expression of α4β2* nicotinic acetylcholine receptors in non-human primates. 
  • Improved synthesis and metabolic stability analysis of the dopamine transporter ligand [(18)F]FECT. 
  • Improved synthesis of N-succinimidyl 4-[18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment. 
  • In vitro characterization of 6-[18F]fluoro-A-85380, a high-affinity ligand for alpha4beta2* nicotinic acetylcholine receptors. 
  • Individual differences in dopamine D2 receptor availability correlate with reward valuation. 
  • Intended Versus Inferred Treatment After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. 
  • Interpretation variability of 18FDG-positron emission tomography studies in dementia. 
  • Ischemic hibernating myocardium demonstrated by positron emission tomography in anomalous origin of the left coronary artery from the pulmonary artery. 
  • Ivory vertebra on 18F-sodium fluoride scan: an old sign in a new modality. 
  • Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[18F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios. 
  • Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative. 
  • Labeling monoclonal antibodies with halogen nuclides. 
  • Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate. 
  • Lack of consistent sex differences in D-amphetamine-induced dopamine release measured with [¹⁸ F]fallypride PET. 
  • Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging. 
  • Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model. 
  • Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. 
  • Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. 
  • Mesolimbic dopamine D2 receptors and neural representations of subjective value. 
  • Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. 
  • NIDA522131, a new radioligand for imaging extrathalamic nicotinic acetylcholine receptors: in vitro and in vivo evaluation. 
  • Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. 
  • No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. 
  • PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment. 
  • Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. 
  • Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. 
  • Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. 
  • Pharmacological and toxicological evaluation of 2-fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a ligand for imaging cerebral nicotinic acetylcholine receptors with positron emission tomography. 
  • Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease. 
  • Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. 
  • Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. 
  • Preclinical evaluation and PET imaging of 18F-labeled Mel-14 F(ab')2 fragment in normal dogs. 
  • Preliminary validation of varicella zoster virus thymidine kinase as a novel reporter gene for PET. 
  • Primary muscle lymphoma: clinical and imaging findings. 
  • Pulmonary abnormalities and PET data analysis: a retrospective study. 
  • Quantification of alpha4beta2* nicotinic receptors in the rat brain with microPET and 2-[18F]F-A-85380. 
  • Reply: Pharmacokinetic and Pharmacodynamic Modifiers of EF5 Uptake and Binding. 
  • Role of Non-FDG-PET/CT in Head and Neck Cancer. 
  • Scintigraphic evaluation of the ocular disposition of 18F-imirestat in rabbits. 
  • Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. 
  • Synthesis and Preliminary Evaluation of 5-[18F]fluoroleucine. 
  • Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. 
  • Synthesis and evaluation of 18F- and 11C-labeled phenyl-galactopyranosides as potential probes for in vivo visualization of LacZ gene expression using positron emission tomography. 
  • Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. 
  • Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG. 
  • Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. 
  • Synthesis and preliminary evaluation of 18F- or 11C-labeled bicyclic nucleoside analogues as potential probes for imaging varicella-zoster virus thymidine kinase gene expression using positron emission tomography. 
  • Synthesis and preliminary evaluation of para- and meta-[18F]fluorobenzylguanidine. 
  • Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography. 
  • Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F. 
  • Synthesis, fluorine-18 radiolabeling, and in vitro characterization of 1-iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivatives as potential PET radioligands for imaging peripheral benzodiazepine receptor. 
  • Talc pleurodesis simulating pleural metastases on 18F-fluorodeoxyglucose positron emission tomography. 
  • The effect of metabolic milieu on cardiac PET imaging using fluorine-18-deoxyglucose and nitrogen-13-ammonia in normal volunteers. 
  • The role of PET scanning in the detection of recurrent cervical cancer. 
  • Thoracic FDG PET: state of the art. 
  • Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. 
  • Tissue distribution studies of [18F]haloperidol, [18F]-beta-(4-fluorobenzoyl)propionic acid, and [82Br]bromperidol by external scintigraphy. 
  • Up-regulation of nicotinic acetylcholine receptors in menthol cigarette smokers. 
  • Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. 
  • Utility of FDG PET/CT in inflammatory cardiovascular disease. 
  • Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. 
  • Validation of an extracerebral reference region approach for the quantification of brain nicotinic acetylcholine receptors in squirrel monkeys with PET and 2-18F-fluoro-A-85380. 
  • [18F]Fluoro-L-dopa PET/CT in congenital hyperinsulinism. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Charles, Hal Cecil, Adjunct Associate Professor in the Department of Radiology, Radiology
  • Chitneni, Satish K., Associate Professor in Radiology, Radiology
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology